• Home
  •  / Pressure BioSciences

Pressure BioSciences

OverviewSuggest Edit

Pressure BioSciences, Inc. (PBI), a life sciences company, engages in the research, development, and commercialization of sample preparation system. It focuses on the development of a platform technology, called pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The Company offers Barocycler instrument and an internally developed disposable PULSE (Pressure Used to Lyse Samples for Extraction) Tubes, which together make up the PCT sample preparation system.

TypePublic
Founded2004
HQEaston, USMap
Websitepressurebiosciences.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)17(+22%)
Revenue (FY, 2019)$1.8 M(-26%)
Share Price (Sept 2020)$1.8
Cybersecurity ratingCMore

Key People/Management at Pressure BioSciences

Richard T. Schumacher

Richard T. Schumacher

President, Chief Executive Officer and Director
Jeffrey N. Peterson

Jeffrey N. Peterson

Chairman of the Board
Edmund Ting

Edmund Ting

Senior Vice President of Engineering
Vito J. Mangiardi

Vito J. Mangiardi

Director
Kevin A. Pollack

Kevin A. Pollack

Director
Alexander Lazarev

Alexander Lazarev

Chief Science Officer
Show more

Pressure BioSciences Office Locations

Pressure BioSciences has offices in Easton and Medford
Easton, US (HQ)
14 Norfolk Ave, South Easton
Medford, US
200 Boston Ave #1950
Show all (2)

Pressure BioSciences Financials and Metrics

Pressure BioSciences Revenue

Pressure BioSciences's revenue was reported to be $1.81 m in FY, 2019
USD

Revenue (Q2, 2020)

268.2k

Gross profit (Q2, 2020)

133.3k

Gross profit margin (Q2, 2020), %

49.7%

Net income (Q2, 2020)

(4.6m)

EBIT (Q2, 2020)

(1.3m)

Market capitalization (14-Sept-2020)

6.5m

Closing stock price (14-Sept-2020)

1.8

Cash (30-Jun-2020)

41.5k

EV

19.9m
Pressure BioSciences's current market capitalization is $6.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

987.7k1.2m1.5m1.4m1.8m2.0m2.2m2.5m1.8m

Revenue growth, %

10%

Cost of goods sold

609.1k834.0k1.3m1.3m1.2m

Gross profit

1.2m1.1m967.1k1.2m612.9k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

190.7k280.4k305.7k324.9k297.9k370.7k357.7k420.8k404.1k307.5k372.5k440.1k413.1k580.3k510.5k511.0k535.3k551.4k540.4k646.1k610.8k639.0k521.8k510.2k518.7k501.2k253.9k268.2k

Cost of goods sold

108.7k175.2k209.8k221.7k243.1k262.9k236.0k287.3k328.7k324.8k270.0k234.3k309.7k304.2k285.8k175.1k134.9k

Gross profit

189.2k237.9k370.5k288.8k267.9k272.4k315.4k253.1k317.3k286.0k369.0k287.4k200.5k214.5k215.4k78.7k133.3k

Gross profit Margin, %

64%58%64%57%52%51%57%47%49%47%58%55%39%41%43%31%50%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

222.8k1.5k31.4k473.9k116.8k138.4k81.0k103.1k29.6k

Accounts Receivable

269.2k216.3k147.6k272.0k113.3k206.8k474.8k229.4k

Prepaid Expenses

143.6k83.4k85.6k104.2k213.9k214.7k170.7k213.5k

Inventories

1.1m923.4k736.7k850.6k1.0m258.1k857.7k765.5k617.7k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

234.4k297.0k15.5k20.9k50.3k167.9k113.7k66.7k428.5k9.4k98.2k220.3k38.2k76.9k93.4k71.6k41.9k121.4k201.3k18.7k81.2k18.5k5.9k269.7k117.9k135.4k31.8k41.5k

Accounts Receivable

159.0k115.0k204.0k241.7k294.9k278.0k314.2k200.9k178.4k190.7k335.0k323.4k350.0k362.8k393.9k511.1k589.7k518.7k564.0k548.3k322.6k526.1k374.3k443.2k410.6k411.4k120.9k121.3k

Prepaid Expenses

80.4k128.3k269.8k374.6k510.4k103.7k53.4k61.0k229.0k157.6k120.1k127.0k151.5k74.4k337.5k145.0k180.0k207.7k175.9k146.3k199.3k202.7k254.5k183.3k127.7k239.2k203.9k192.6k

Inventories

1.1m1.1m1.0m975.9k905.7k890.9k866.6k851.5k786.8k853.2k852.5k799.0k783.9k808.8k966.5k1.0m1.0m940.4k1.1m1.1m892.4k900.1k899.9k753.1k744.8k713.9k655.8k614.9k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.0m)(3.5m)(4.1m)(4.6m)(7.4m)(2.7m)(10.7m)(9.7m)(11.7m)

Depreciation and Amortization

141.3k107.5k79.6k65.7k25.3k17.9k8.6k94.3k123.6k

Inventories

48.6k95.7k186.7k(113.9k)(187.8k)133.1k(112.0k)(56.1k)78.8k

Accounts Payable

763.8k309.2k(97.1k)(67.0k)(94.4k)(534.1k)182.0k69.6k156.9k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.6m)(2.2m)(1.1m)(1.6m)(2.4m)(779.4k)(1.8m)(2.5m)(1.8m)(2.4m)(3.3m)(2.0m)(2.8m)(3.4m)(6.0m)(5.0m)(5.9m)(5.6m)(6.2m)(7.9m)(2.2m)(4.5m)(6.3m)(2.1m)(4.8m)(8.0m)(4.0m)(8.5m)

Depreciation and Amortization

77.0k109.5k29.3k57.2k82.4k21.5k40.4k63.0k19.6k39.7k59.4k6.9k12.2k18.3k6.2k12.3k15.5k2.5k4.7k7.0k23.5k45.9k70.7k23.6k47.2k68.8k45.0k74.2k

Inventories

(29.8k)(4.1k)47.7k93.1k(163.4k)32.5k56.7k71.9k(50.1k)(116.5k)(115.8k)51.6k66.7k41.7k71.8k36.0k30.2k(35.1k)(226.2k)(217.5k)(14.8k)(2.5k)(2.4k)12.3k20.7k51.6k(38.1k)2.9k

Accounts Payable

276.5k537.2k238.8k304.9k399.1k(140.5k)(116.6k)1.9k(90.0k)59.3k(17.0k)(115.7k)(56.3k)(201.0k)(161.3k)(51.5k)(409.2k)265.5k338.8k445.9k51.8k108.7k16.4k(184.4k)152.3k838.3k54.5k(5.9k)
show all
USDQ2, 2011

Financial Leverage

4.5 x
Show all financial metrics

Pressure BioSciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

Learn more about about our premium products
SecurityScorecard logo

Pressure BioSciences Online and Social Media Presence

Pressure BioSciences's Trends

Embed Graph

Pressure BioSciences News and Updates

August 12, 2020

Pressure BioSciences Awarded Pivotal U.S. Patent for Novel, High Pressure Enhanced Consumable Device

SOUTH EASTON, Mass., Aug. 12, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide Life Sciences and other...
December 30, 2019

Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.

SOUTH EASTON, Mass., Dec. 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sci…
December 19, 2019

Pressure BioSciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

Significant Revenue Growth Reported in Consumable Products (158%) and Scientific Services (87%);Company Continues to Gain Momentum in Its PCT, BaroFold, and UST Technology Platforms
October 04, 2019

Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.

SOUTH EASTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sci…
September 17, 2019

Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer

Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team    South Easton, MA - (NewMediaWire) - September 17, 2019 - Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a lead…
August 22, 2019

Pressure BioSciences Announces Two More Purchase Orders for its Revolutionary BaroShear K45 Processing System for Manufacturing Water-Soluble CBD

Company Forecasts All 12 Systems in Current Build Cycle Will Be Sold by September 30, 2019 and Reiterates Previous Guidance for More Than Doubling of Annual Revenue in 2020  South Easton, MA - (NewMediaWire) - August 22, 2019 - Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a l…
Show more

 Pressure BioSciences Frequently Asked Questions

  • When was Pressure BioSciences founded?

    Pressure BioSciences was founded in 2004.

  • Who are Pressure BioSciences key executives?

    Pressure BioSciences's key executives are Richard T. Schumacher, Jeffrey N. Peterson and Edmund Ting.

  • How many employees does Pressure BioSciences have?

    Pressure BioSciences has 17 employees.

  • What is Pressure BioSciences revenue?

    Latest Pressure BioSciences annual revenue is $1.8 m.

  • What is Pressure BioSciences revenue per employee?

    Latest Pressure BioSciences revenue per employee is $106.5 k.

  • Who are Pressure BioSciences competitors?

    Competitors of Pressure BioSciences include NxStage Medical, SteadyMed Therapeutics and ResMed.

  • Where is Pressure BioSciences headquarters?

    Pressure BioSciences headquarters is located at 14 Norfolk Ave, South Easton, Easton.

  • Where are Pressure BioSciences offices?

    Pressure BioSciences has offices in Easton and Medford.

  • How many offices does Pressure BioSciences have?

    Pressure BioSciences has 2 offices.